Aveanna Healthcare Holdings Inc (AVAH) valuation
Aveanna Healthcare P/E ratio history
Aveanna Healthcare trades at 10.4 times its earnings over the last twelve months and 15.2 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Jan 3, 2026 | $8.08 | $1.05 | 7.7 |
| Dec 28, 2024 | $4.66 | -$0.06 | n/m |
| Dec 30, 2023 | $2.68 | -$0.71 | n/m |
| Dec 31, 2022 | $0.78 | -$3.57 | n/m |
| Jan 1, 2022 | $7.40 | -$0.69 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Aveanna Healthcare valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Aveanna HealthcareAVAH | $2.87B | 10.4 | 15.2 | 1.1 |
| Ideaya BiosciencesIDYA | $2.81B | — | — | 12.0 |
| Beam TherapeuticsBEAM | $2.80B | — | — | 18.0 |
| Nurix TherapeuticsNRIX | $2.78B | 11.7 | — | 4.0 |
| Dyne TherapeuticsDYN | $2.76B | — | — | — |
| Denali TherapeuticsDNLI | $3.01B | — | — | 834.1 |
| Privia Health GroupPRVA | $2.71B | 97.6 | 22.0 | 1.2 |
| Surgery PartnersSGRY | $3.04B | — | 82.2 | 0.9 |
| Enliven TherapeuticsELVN | $2.69B | — | — | — |
| Peer median | 54.6 | 52.1 | 8.0 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: AVAH financials · AVAH returns
No forecast, no recommendation. This page describes Aveanna Healthcare Holdings Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.